{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T23:57:18Z","timestamp":1790899038777,"version":"4.1.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2013,10,16]],"date-time":"2013-10-16T00:00:00Z","timestamp":1381881600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1007\/s10157-013-0875-8","type":"journal-article","created":{"date-parts":[[2013,10,15]],"date-time":"2013-10-15T02:07:42Z","timestamp":1381802862000},"page":"234-237","source":"Crossref","is-referenced-by-count":100,"title":["Causes and consequences of lipoprotein(a) abnormalities in kidney disease"],"prefix":"10.1007","volume":"18","author":[{"given":"Florian","family":"Kronenberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,10,16]]},"reference":[{"key":"875_CR1","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1365-2796.2012.02592.x","volume":"273","author":"F Kronenberg","year":"2013","unstructured":"Kronenberg F, Utermann G. Lipoprotein(a)\u2014resurrected by genetics. J Intern Med. 2013;273:6\u201330.","journal-title":"J Intern Med"},{"key":"875_CR2","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1172\/JCI113093","volume":"80","author":"G Utermann","year":"1987","unstructured":"Utermann G, Menzel HJ, Kraft HG, Duba HC, Kemmler HG, Seitz C. Lp(a) glycoprotein phenotypes: inheritance and relation to Lp(a)-lipoprotein concentrations in plasma. J Clin Invest. 1987;80:458\u201365.","journal-title":"J Clin Invest"},{"key":"875_CR3","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/jama.2009.1063","volume":"302","author":"S Erqou","year":"2009","unstructured":"Erqou S, Kaptoge S, Perry PL, et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA. 2009;302:412\u201323.","journal-title":"JAMA"},{"key":"875_CR4","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1161\/01.ATV.12.10.1214","volume":"12","author":"C Sandholzer","year":"1992","unstructured":"Sandholzer C, Saha N, Kark JD, et al. Apo(a) isoforms predict risk for coronary heart disease: a study in six populations. Arterioscler Thromb. 1992;12:1214\u201326.","journal-title":"Arterioscler Thromb"},{"key":"875_CR5","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/BF00201550","volume":"86","author":"C Sandholzer","year":"1991","unstructured":"Sandholzer C, Hallman DM, Saha N, et al. Effects of the apolipoprotein(a) size polymorphism on the lipoprotein(a) concentration in 7 ethnic groups. Hum Genet. 1991;86:607\u201314.","journal-title":"Hum Genet"},{"key":"875_CR6","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1161\/01.ATV.16.6.713","volume":"16","author":"HG Kraft","year":"1996","unstructured":"Kraft HG, Lingenhel A, K\u00f6chl S, et al. Apolipoprotein(a) Kringle IV repeat number predicts risk for coronary heart disease. Arterioscler Thromb Vasc Biol. 1996;16:713\u20139.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"875_CR7","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1016\/j.jacc.2009.10.080","volume":"55","author":"S Erqou","year":"2010","unstructured":"Erqou S, Thompson A, Di AE, et al. Apolipoprotein(a) isoforms and the risk of vascular disease: systematic review of 40 studies involving 58,000 participants. J Am Coll Cardiol. 2010;55:2160\u20137.","journal-title":"J Am Coll Cardiol"},{"key":"875_CR8","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1194\/jlr.M800174-JLR200","volume":"49","author":"C Bergmark","year":"2008","unstructured":"Bergmark C, Dewan A, Orsoni A, et al. A novel function of lipoprotein[a] as a preferential carrier of oxidized phospholipids in human plasma. J Lipid Res. 2008;49:2230\u20139.","journal-title":"J Lipid Res"},{"key":"875_CR9","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1161\/ATVBAHA.107.145805","volume":"27","author":"S Kiechl","year":"2007","unstructured":"Kiechl S, Willeit J, Mayr M, et al. Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity and 10-year cardiovascular outcomes: prospective results from the Bruneck study. Arterioscler Thromb Vasc Biol. 2007;27:1788\u201395.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"875_CR10","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1016\/j.jacc.2006.03.001","volume":"47","author":"S Tsimikas","year":"2006","unstructured":"Tsimikas S, Kiechl S, Willeit J, et al. Oxidized phospholipids predict the presence and progression of carotid and femoral atherosclerosis and symptomatic cardiovascular disease: five-year prospective results from the Bruneck Study. J Am Coll Cardiol. 2006;47:2219\u201328.","journal-title":"J Am Coll Cardiol"},{"key":"875_CR11","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.jacc.2010.04.048","volume":"56","author":"S Tsimikas","year":"2010","unstructured":"Tsimikas S, Mallat Z, Talmud PJ, et al. Oxidation-specific biomarkers, lipoprotein(a), and risk of fatal and nonfatal coronary events. J Am Coll Cardiol. 2010;56:946\u201355.","journal-title":"J Am Coll Cardiol"},{"key":"875_CR12","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/MOL.0b013e328308b622","volume":"19","author":"S Tsimikas","year":"2008","unstructured":"Tsimikas S, Witztum JL. The role of oxidized phospholipids in mediating lipoprotein(a) atherogenicity. Curr Opin Lipidol. 2008;19:369\u201377.","journal-title":"Curr Opin Lipidol"},{"key":"875_CR13","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/S0022-2275(20)37150-9","volume":"38","author":"F Kronenberg","year":"1997","unstructured":"Kronenberg F, Trenkwalder E, Lingenhel A, et al. Renovascular arteriovenous differences in Lp(a) plasma concentrations suggest removal of Lp(a) from the renal circulation. J Lipid Res. 1997;38:1755\u201363.","journal-title":"J Lipid Res"},{"key":"875_CR14","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1172\/JCI119055","volume":"98","author":"V Mooser","year":"1996","unstructured":"Mooser V, Marcovina SM, White AL, Hobbs HH. Kringle-containing fragments of apolipoprotein(a) circulate in human plasma and are excreted into the urine. J Clin Invest. 1996;98:2414\u201324.","journal-title":"J Clin Invest"},{"key":"875_CR15","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1161\/01.ATV.16.8.905","volume":"16","author":"KM Kostner","year":"1996","unstructured":"Kostner KM, Maurer G, Huber K, et al. Urinary excretion of apo(a) fragments. Role in apo(a) catabolism. Arterioscler Thromb Vasc Biol. 1996;16:905\u201311.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"875_CR16","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1681\/ASN.V111105","volume":"11","author":"F Kronenberg","year":"2000","unstructured":"Kronenberg F, Kuen E, Ritz E, et al. Lipoprotein(a) serum concentrations and apolipoprotein(a) phenotypes in mild and moderate renal failure. J Am Soc Nephrol. 2000;11:105\u201315.","journal-title":"J Am Soc Nephrol"},{"key":"875_CR17","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1172\/JCI116213","volume":"91","author":"H Dieplinger","year":"1993","unstructured":"Dieplinger H, Lackner C, Kronenberg F, et al. Elevated plasma concentrations of lipoprotein(a) in patients with end-stage renal disease are not related to the size polymorphism of apolipoprotein(a). J Clin Invest. 1993;91:397\u2013401.","journal-title":"J Clin Invest"},{"key":"875_CR18","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1681\/ASN.V61110","volume":"6","author":"F Kronenberg","year":"1995","unstructured":"Kronenberg F, K\u00f6nig P, Neyer U, et al. Multicenter study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis. J Am Soc Nephrol. 1995;6:110\u201320.","journal-title":"J Am Soc Nephrol"},{"key":"875_CR19","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1046\/j.1523-1755.1998.00880.x","volume":"53","author":"P Stenvinkel","year":"1998","unstructured":"Stenvinkel P, Heimb\u00fcrger O, Tuck CH, Berglund L. Apo(a)-isoform size, nutritional status and inflammatory markers in chronic renal failure. Kidney Int. 1998;53:1336\u201342.","journal-title":"Kidney Int"},{"key":"875_CR20","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1046\/j.1523-1755.1999.00273.x","volume":"55","author":"J Zimmermann","year":"1999","unstructured":"Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int. 1999;55:648\u201358.","journal-title":"Kidney Int"},{"key":"875_CR21","doi-asserted-by":"crossref","first-page":"263","DOI":"10.7326\/0003-4819-119-4-199308150-00002","volume":"119","author":"C Wanner","year":"1993","unstructured":"Wanner C, Rader D, Bartens W, et al. Elevated plasma lipoprotein(a) in patients with the nephrotic syndrome. Ann Intern Med. 1993;119:263\u20139.","journal-title":"Ann Intern Med"},{"key":"875_CR22","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/j.1523-1755.2004.00418.x","volume":"65","author":"F Kronenberg","year":"2004","unstructured":"Kronenberg F, Lingenhel A, Lhotta K, et al. The apolipoprotein(a) size polymorphism is associated with nephrotic syndrome. Kidney Int. 2004;65:606\u201312.","journal-title":"Kidney Int"},{"key":"875_CR23","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1038\/sj.ki.5002131","volume":"71","author":"ME Frischmann","year":"2007","unstructured":"Frischmann ME, Kronenberg F, Trenkwalder E, et al. In vivo turnover study demonstrates diminished clearance of lipoprotein(a) in hemodialysis patients. Kidney Int. 2007;71:1036\u201343.","journal-title":"Kidney Int"},{"key":"875_CR24","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1681\/ASN.V981474","volume":"9","author":"MGM Velden De Sain-van der","year":"1998","unstructured":"De Sain-van der Velden MGM, Reijngoud DJ, Kaysen GA, et al. Evidence for increased synthesis of lipoprotein(a) in the nephrotic syndrome. J Am Soc Nephrol. 1998;9:1474\u201381.","journal-title":"J Am Soc Nephrol"},{"key":"875_CR25","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1161\/01.ATV.14.9.1399","volume":"14","author":"F Kronenberg","year":"1994","unstructured":"Kronenberg F, K\u00f6nig P, Lhotta K, et al. Apolipoprotein(a) phenotype-associated decrease in lipoprotein(a) plasma concentrations after renal transplantation. Arterioscler Thromb. 1994;14:1399\u2013404.","journal-title":"Arterioscler Thromb"},{"key":"875_CR26","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/sj.ejhg.5201016","volume":"11","author":"F Kronenberg","year":"2003","unstructured":"Kronenberg F, Lhotta K, K\u00f6nig P, Margreiter R, Dieplinger H, Utermann G. Apolipoprotein(a) isoform-specific changes of lipoprotein(a) after kidney transplantation. Eur J Hum Genet. 2003;11:693\u20139.","journal-title":"Eur J Hum Genet"},{"key":"875_CR27","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S0021-9150(99)00014-3","volume":"144","author":"L Kerschdorfer","year":"1999","unstructured":"Kerschdorfer L, K\u00f6nig P, Neyer U, et al. Lipoprotein(a) plasma concentrations after renal transplantation: a prospective evaluation after 4\u00a0years of follow-up. Atherosclerosis. 1999;144:381\u201391.","journal-title":"Atherosclerosis"},{"key":"875_CR28","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1373\/clinchem.2010.146779","volume":"56","author":"S Mora","year":"2010","unstructured":"Mora S, Kamstrup PR, Rifai N, Nordestgaard BG, Buring JE, Ridker PM. Lipoprotein(a) and risk of type 2 diabetes. Clin Chem. 2010;56:1252\u201360.","journal-title":"Clin Chem"},{"key":"875_CR29","doi-asserted-by":"crossref","unstructured":"Lamina C, Kronenberg F. The mysterious lipoprotein(a) is still good for a surprise. Lancet Diabetes Endocrinol. 2013. doi: 10.1016\/S2213-8587(13)70085-8 .","DOI":"10.1016\/S2213-8587(13)70085-8"},{"key":"875_CR30","doi-asserted-by":"crossref","unstructured":"Kamstrup PR, Nordestgaard BG. Lipoprotein(a) levels, isoform size, and risk of type 2 diabetes: a Mendelian randomisation study. Lancet Diabetes Endocrinol. 2013. doi: 10.1016\/S2213-8587(13)70064-0 .","DOI":"10.1016\/S2213-8587(13)70064-0"},{"key":"875_CR31","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1161\/01.CIR.86.2.475","volume":"86","author":"MD Cressman","year":"1992","unstructured":"Cressman MD, Heyka RJ, Paganini EP, O\u2019Neil J, Skibinski CI, Hoff HF. Lipoprotein(a) is an independent risk factor for cardiovascular disease in hemodialysis patients. Circulation. 1992;86:475\u201382.","journal-title":"Circulation"},{"key":"875_CR32","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1681\/ASN.V1051027","volume":"10","author":"F Kronenberg","year":"1999","unstructured":"Kronenberg F, Neyer U, Lhotta K, et al. The low molecular weight apo(a) phenotype is an independent predictor for coronary artery disease in hemodialysis patients: a prospective follow-up. J Am Soc Nephrol. 1999;10:1027\u201336.","journal-title":"J Am Soc Nephrol"},{"key":"875_CR33","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1681\/ASN.2006091006","volume":"18","author":"BCH Kwan","year":"2007","unstructured":"Kwan BCH, Kronenberg F, Beddhu S, Cheung AK. Lipoprotein metabolism and lipid management in chronic kidney disease. J Am Soc Nephrol. 2007;18:1246\u201361.","journal-title":"J Am Soc Nephrol"},{"key":"875_CR34","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1161\/01.CIR.0000038946.91899.BB","volume":"106","author":"JC Longenecker","year":"2002","unstructured":"Longenecker JC, Klag MJ, Marcovina SM, et al. Small apolipoprotein(a) size predicts mortality in end-stage renal disease: the Choice Study. Circulation. 2002;106:2812\u20138.","journal-title":"Circulation"},{"key":"875_CR35","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1681\/ASN.2004110922","volume":"16","author":"JC Longenecker","year":"2005","unstructured":"Longenecker JC, Klag MJ, Marcovina SM, et al. High lipoprotein(a) levels and small apolipoprotein(a) size prospectively predict cardiovascular events in dialysis patients. J Am Soc Nephrol. 2005;16:1794\u2013802.","journal-title":"J Am Soc Nephrol"}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-013-0875-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10157-013-0875-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-013-0875-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,8]],"date-time":"2022-03-08T22:21:09Z","timestamp":1646778069000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10157-013-0875-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,16]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["875"],"URL":"https:\/\/doi.org\/10.1007\/s10157-013-0875-8","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"value":"1342-1751","type":"print"},{"value":"1437-7799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10,16]]}}}